MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

A Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma

Zi Yun Ng, Mark Bishton, David Ritchie, Robert Campbell, Michael Gilbertson, Kate Hill, Sumita Ratnasingam, Anthony Schwarer, Kate Manos, Sophie Shorten, Melissa Ng, Niles Nelson, Liu Xin, Sanjay De Mel Widanalage, Tenny Sunny, Duncan Purtill, Michelle Poon, Anna Johnston, Tara Cochrane, Hui-Peng Lee, Greg Hapgood, Constantine Tam, Stephen Opat, Eliza Hawkes, John Seymour, Chan Yoon Cheah
Hematological Oncology 2019 April 15
30983008
Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant eligible patients and the optimal approach remains unknown. We performed an international, retrospective study of transplant eligible patients to assess impact of induction chemo-immunotherapy and conditioning regimens on clinical outcomes. We identified 228 patients meeting inclusion criteria. Baseline characteristics were similar among the induction groups except for some variation in age. The type of induction chemo-immunotherapy received did not influence overall response rates (ORR) (0.43), progression free survival (PFS) (P>0.67) or overall survival (OS) (P>0.35) on multivariate analysis (PFS and OS). Delivery of ASCT was associated with favourable PFS and OS (0.01) on univariate analysis only; this benefit was not seen on multivariate analysis - PFS (0.36) and OS (0.21). Compared with BuMel (busulfan and melphalan), the use of the BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning regimen was associated with inferior PFS (HR=2.0 [95%CI 1.1-3.6], 0.02) but not OS (HR=1.1 [95%CI 0.5-2.3] 0.81) on univariate analysis only. Within the limits of a retrospective study and modest power for some comparisons, type of induction therapy did not influence ORR, PFS or OS for transplant eligible patients with MCL. International efforts are required to perform randomized clinical trials evaluating chemo-immunotherapy induction regimens.

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
30983008
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"